Wegovy Weight Loss
- Wegovy (semaglutide) is a weight loss prescription drug manufactured by Novo Nordisk and recommended by NICE for individuals with a BMI over 30kg/m2 and weight-related medical conditions.
- Wegovy works by suppressing appetite and controlling food consumption through its active ingredient, semaglutide, which mimics a hormone responsible for appetite regulation.
- In a 68-week clinical trial, Wegovy, combined with a reduced-calorie diet and increased physical activity, led to 83% of Wegovy users achieving a 5% or greater weight loss, while 66% achieved a 10% or more weight loss, and 30% achieved a remarkable 20% or more weight loss.
- While no medication is entirely risk-free, following the recommended dosing schedule can help minimise common side effects associated with Wegovy.
How does Wegovy work?
Wegovy is administered with a weekly injection works operates by suppressing appetite and controlling the consumption of food. Its active ingredient, semaglutide, imitates the behaviour of a hormone responsible for appetite regulation. Consequently, individuals experience an extended sensation of fullness and reduced hunger. This aids in consuming fewer calories and, ideally, leads to weight loss. GLP-1 agonists like semaglutide also function by enhancing insulin release from the pancreas and reducing the liver’s glucose production, effectively contributing to the reduction of blood sugar levels.
How effective is Wegovy?
In a 68-week medical study of 1,961 adults living with obesity or excess weight with a related medical problem along with a reduced-calorie diet and increased physical activity:
In the study, individuals who were administered a placebo (not receiving medication) experienced an average weight reduction of 6 pounds, equivalent to approximately 2.5% of their initial body weight. The average starting weight for both groups was around 232 pounds.
Furthermore, when coupled with a calorie-restricted meal plan and heightened physical activity, participants taking Wegovy in the study achieved more significant weight loss compared to those on the placebo: 83% of adults who took Wegovy attained a weight loss of 5% or greater, in contrast to 31% of individuals on placebo. Among adults utilising Wegovy, 66% accomplished a weight loss of 10% or more, whereas only 12% of the placebo group achieved this. Notably, 48% of adults utilising Wegovy successfully shed 15% or more of their initial weight, whereas just 5% of the placebo group managed the same level of weight loss.
Remarkably, a substantial 30% of individuals utilising Wegovy accomplished a weight reduction of 20% or more, contrasting with a mere 2% among those who were administered the placebo, demonstrating the effectiveness of the intervention.
Is Wegovy Safe?
Wegovy has been approved by regulatory authorities, such as the U.S. Food and Drug Administration (FDA), so it’s considered very safe. It’s important to note that no medication is entirely without potential risk, the safety of Wegovy should be considered in consultation with a healthcare provider, it’s important to discuss any allergic reactions and family history. There are some common side effects to be aware of, but by following the dosing schedule, they should be minimal.